Literature DB >> 6662169

Kinetics of oral fluphenazine disposition in humans by GC-MS.

K K Midha, G McKay, R Edom, E D Korchinski, E M Hawes, K Hall.   

Abstract

The disposition of fluphenazine was investigated in six healthy volunteers following oral administration (5 mg). Using a sensitive and specific GC-MS procedure plasma fluphenazine concentrations were measured up until 32 h after drug administration. Peak plasma concentrations varied widely (range: 0.26-1.06 ng/ml) and were observed at 2.8 +/- 0.5 h following fluphenazine administration. The apparent terminal elimination half-life of fluphenazine was 33.1 +/- 8.1 h. The area under the plasma concentration-time curve differed widely between subjects (range: 7.1-28.6 ng/ml h) suggesting large interindividual differences in the extent of fluphenazine presystemic elimination.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6662169     DOI: 10.1007/bf00542363

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Fluphenazine, trifluoperazine and perphenazine in Vacutainers.

Authors:  K K Midha; J K Cooper; Y D Lapierre; J W Hubbard
Journal:  Can Med Assoc J       Date:  1981-02-01       Impact factor: 8.262

Review 2.  Presystemic drug elimination.

Authors:  P A Routledge; D G Shand
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

3.  Subnanogram determination of fluphenazine in human plasma by gas chromatography mass spectrometry.

Authors:  G McKay; K Hall; R Edom; E M Hawes; K K Midha
Journal:  Biomed Mass Spectrom       Date:  1983-10

4.  Kinetics of oral trifluoperazine disposition in man.

Authors:  K K Midha; E D Korchinski; R K Verbeeck; R M Roscoe; E M Hawes; J K Cooper; G McKay
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

5.  Radioimmunoassay for fluphenazine in human plasma.

Authors:  K K Midha; J K Cooper; J W Hubbard
Journal:  Commun Psychopharmacol       Date:  1980

6.  Pharmacokinetics of chlorpromazine in normal volunteers.

Authors:  J C Loo; K K Midha; I J McGilveray
Journal:  Commun Psychopharmacol       Date:  1980

7.  Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.

Authors:  S H Curry; R Whelpton; P J de Schepper; S Vranckx; A A Schiff
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

8.  Fluphenazine determination in human plasma by a sensitive gas chromatographic method using nitrogen detector.

Authors:  J I Javaid; H Dekirmenjian; U Liskevych; R L Lin; J M Davis
Journal:  J Chromatogr Sci       Date:  1981-09       Impact factor: 1.618

9.  Fluphenazine pharmacokinetics and therapeutic response.

Authors:  M W Dysken; J I Javaid; S S Chang; C Schaffer; A Shahid; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Sensitive gas-chromatographic determination of fluphenazine in human plasma.

Authors:  M Franklin; D H Wiles; D J Harvey
Journal:  Clin Chem       Date:  1978-01       Impact factor: 8.327

View more
  5 in total

1.  Single-dose kinetics of the neuroleptic drug perazine in psychotic patients.

Authors:  U Breyer-Pfaff; K Nill; H W Schied; H J Gaertner; H Giedke
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 2.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

3.  Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine.

Authors:  S J Dencker; R Johansson; U Malm
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients.

Authors:  K K Midha; E M Hawes; J W Hubbard; E D Korchinski; G McKay
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 5.  Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

Authors:  G V Milton; M W Jann
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.